Genetic polymorphisms in sepsis

Pediatric Critical Care Medicine

Volumn 6, Issue 3 SUPPL., 2005, Pages

  Dahmer, Mary K ^a   Randolph, Adrienne ^b   Vitali, Sally ^b   Quasney, Michael W ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Genetics; Outcome; Polymorphism; Predisposition; Sepsis

Indexed keywords

CD14 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FC RECEPTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MANNOSE BINDING LECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR SUBTYPE; SURFACTANT PROTEIN B; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CRITICAL ILLNESS; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HOST; HUMAN; IMMUNE SYSTEM; MEDICAL LITERATURE; MOLECULAR RECOGNITION; MORTALITY; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS; STIMULUS RESPONSE; SYMPTOMATOLOGY;

ADULT; ANIMALS; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; POLYMORPHISM, GENETIC; SEPSIS;

EID: 19444378437     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000161970.44470.C7     Document Type: Review

References (190)

1. Sorensen TI, Nielsen GG, Andersen PK, et al: Genetic and environmental influences on premature death in adult sepsis. N Engl J Med 1988; 318:727-732
2. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
3. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans: Advances in the understanding or pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
4. Walley KR, Lukacs NW, Standiford TJ, et al: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64:4733-4738
5. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 1996; 77:110-117
6. Parrillo JE: Pathogenic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-1477
7. Poltorak A, He X, Smirnova I, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in the Tlr4 gene. Science 1998; 282:2085-2088
8. Chow JC, Young DW, Golenbock DT, et al: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274:10689-10692
9. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-787
10. Beutler B, Poltorak A: Sepsis and evolution of the innate immune response. Crit Care Med 2001; 29:S2-S7
11. Ulevitch RJ: Regulation of receptor-dependent activation of the innate immune response. J Infect Dis 2003; 187:S351-S355
12. Hoshino K, Takeuchi O, Kawai, T et al: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the LPS gene product. J Immunol 1999; 162: 3749-3752
13. Qureshi ST, Lariviere L, Leveque G, et al: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). J Exp Med 1999; 189:615-625
14. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191
15. Michel O, LeVan TD, Stern D, et al: Systemic responsiveness to lipopolysaccharide and polymorphisms in the Toll-like receptor 4 gene in human beings. J Allergy Clin Immunol 2003; 112:923-929
16. Werner M, Topp R, Wimmer K, et al: TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003; 112: 323-330
17. Schippers EF, van't Veer C, van Voorden S, et al: TNF-alpha promoter, Nod2 and Toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine 2004; 26:16-24
18. Heesen M, Bloemeke B, Kunz D: The cytokine synthesis by heterozygous carriers of the Toll-like receptor 4 asp299bly polymorphism does not differ from that of wild type homozygotes. Eur Cytokine Netw 2003; 14: 234-237
19. von Aulock S, Schroder NWJ, Gueinzius K, et al: Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938-943
20. Imahara SD, Jelacic S, Junker CE, et al: The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005; 6:37-43
21. Agnese DM, Calvano JE, Hahm SJ, et al: Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis 2002; 186:1522-1525
22. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032
23. Child NJA, Yang IA, Pulletz MCK, et al: Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003; 31: 652-653
24. Read RC, Pullin J, Gregory S, et al: A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184:640-642
25. Smirnova I, Mann N, Dols A, et al: Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Nat Acad Sci U S A 2003; 100:6075-6080
26. Pridmore AC, Wyllie DH, Abdillahi F, et al: A lipopolysaccharide-deficient mutant of Neisseria meningitides elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TKR4/MD2. J Infect Dis 2001; 183:89-96
27. Ingalls RR, Lien E, Golenbock T: Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitides activate the inflammatory response through Toll-like receptor 2. Infect Immun 2001; 69:2230-2236
28. Moore KJ, Andersson LP, Ingalls RR, et al: Divergent responses to LPS and bacteria in CD14-deficient murine macrophages. J Immunol 2000; 165:4272-4280
29. Unkelback K, Gardemann A, Kostrzewa M, et al: A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atheroslcerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19:932-938
30. Baldini M, Lohman IC, Halonene M, et al: A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-983
31. Hubacek JA, Pitha J, Skodova Z, et al: C(-260) to T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-3220
32. LeVan TD, Bloom JW, Bailey TJ, et al: A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001; 167: 5834-5844
33. Koenig W, Khuseyinova N, Hoffman MM, et al: CD14 C(-260) ->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002; 40:43-42
34. Gibot S, Cariou A, Drouet L, et al: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30:969-973
35. Heesen M, Bloemeke B, Schade U, et al: The -260C to T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intens Care Med 2002; 28:1161-1163
36. Hubacek JA, Stuber F, Frohlich D, et al: The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2001; 1:405-407
37. van der Pol WL, van de Winkel JGJ: IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 1998; 48:222-232
38. van Sorge NM, van der Pol WL, van de Winkel JGJ: FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61: 189-202
39. Wu J, Edberg JC, Redecha PB, et al: A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100:1059-1070
40. Koene HR, Kleijer M, Algra J, et al: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gamma RIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114
41. Huizinga TW. Kleijer M, Tetteroo PA, et al: Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phosphor-inositol-linked Fc gamma receptor III (CD16). Blood 1990; 75:213-217
42. Salmon JE, JC Edberg, RP Kimberly: Fc gamma receptor III on human neutrophils: Allelic variants have functionally distinct capacities. J Clin Invest 1990; 85:1287-1295
43. Salmon JE, Millard SS, Brogle NL, et al: Fc gamma receptor IIIb enhances Fc gamma receptor IIa function in an oxidant-dependent and allele-sensitive manner. J Clin Invest 1995; 95:2877-2885
44. Warmerdam PA, van de Winkel JG, Gosselin EJ, et al: Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med 1990; 172:19-25
45. Warmerdam PA, van de Winkel JG, Vlug A, et al: A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147:1338-1343
46. Salmon JE, Edberg JC, Brogle NL, et al: Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB: Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89:1274-1281
47. Sanders LA, Feldman RG, Voorhorst-Ogink MM, et al: Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63:73-81
48. Herman DJ, Hamilton RG, Barington T, et al: Quantitation of human IgG subclass antibodies to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods 1992; 148:101-114
49. Siber GR, Schur PH, Aisenberg AC, et al: Correlation between serum IgG2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178-182
50. Fijen CA, Bredius RG, Kuijper EJ: Polymorphism of IgG Fc receptors in meningococcal disease. Ann Intern Med 1993; 119:636
51. Bredius RG, Derkx BH, Fijen CA, et al: Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170:848-853
52. Platonov E, Shipulin GA, Vershinina IV, et al: Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27:746-750
53. Platanov AE, Kuijper EJ, Vershinina IV, et al: Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement-deficient individuals. Clin Exp Immunol 1998; 111:97-101
54. Domingo P, Muniz-Diaz E, Baraldes MA, et al: Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002; 112:19-25
55. van der Pol WL, Huizinga TW, Vidarsson G, et al: Relevance of Fc gamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001; 184: 1548-1555
56. Yee AMF, Phan HM, Zuniga R, et al: Association between FcγRIIa-R131 allotype and bacteremic Pneumococcal pneumonia. Clin Infect Dis 2000; 30:25-28
57. Lieke A, Sanders M, van de Winkel JGJ, et al: Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170: 854-861
58. Tezcan I, Berkel AI, Ersoy F, et al: Fc gamma receptor allotypes in children with bacterial meningitis: A preliminary study. Turk J Pediatr 1998; 40:533-538
59. Smith I, Vedeler C, Halstensen A: FcγRIIa and FcγRIIIb polymorphisms were not associated with meningococcal disease in Western Norway. Epidemiol Infect 2003; 130:193-199
60. Turner MW: Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199:327-339
61. Kuhlman M, Joiner K, Ezekowitz RA: The human mannose-binding protein functions as an opsonin. J Exp Med 1989; 169: 1733-1745
62. Matsushita M, Endo Y, Fujita T: MASP1 (MBL-associated serine protease 1). Immunobiology 1998; 199:340-347
63. Summerfield JA, Ryder S, Sumiya M, et al: Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345:886-889
64. Sastry K, Herman GA, Day L, et al: The human mannose-binding protein gene: exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989; 170:1175-1189
65. Sumiya M, Super M, Tabona P, et al: Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337: 1569-1570
66. Lipscombe RJ, Sumiya M, Hill AV, et al: High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1:709-715
67. Madsen HO, Garred P, Thiel S, et al: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-3020
68. Summerfield JA, Sumiya M, Levin M, et al: Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314:1229-1232
69. Koch A, Melbye M, Sorensen P, et al: Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001; 285:1316-1321
70. Hibberd ML, Sumiya M, Summerfield JA, et al: Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353:1049-1053
71. Garred P, Madsen HO, Halberg P, et al: Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42:2145-2152
72. Gomi K, Tokue Y, Kobayashi T, et al: Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest 2004; 126:95-99
73. Roy S, Knox K, Segal S, et al: MBL genotype and risk of invasive pneumococcal disease: A case control study. Lancet 2002; 359: 1569-1573
74. Kronborg G, Weis N, Madsen HO, et al: Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. JID 2002; 185: 1517-1520
75. Nathan C: Points of control in inflammation. Nature 2002; 420:846-852
76. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420:885-891
77. Furman WL, Strother D, McClain K, et al: Phase I clinical trail of recombinant tumor necrosis factor in children with refractory solid tumors: A pediatric oncology group study. J Clin Oncol 1993; 11:2205-2210
78. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-473
79. Wheeler AP, Jesmok G, Brigham KL: Tumor necrosis factor's effects on lung mechanics, gas exchange, and airway reactivity in sheep. J Appl Physiol 1990; 68:2542-2549
80. Selleri C, Sato T, Anderson S, et al: Interferon-γ and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165:538-546
81. van Hinsbergh VWM, Bauer KA, Kooistra T, et al: Progress of fibrinolysis during tumor necrosis factor infusions in humans: Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrinogen degradation products. Blood 1990; 76:2284-2289
82. Stuber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
83. Pociot F, Briant L, Jongeneel CV, et al: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23:224-231
84. Appoloni O, Dupont E, Vandercruys M, et al: The association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock. Am J Med 2001; 110:486-488
85. Louis E, Franchimont D, Piron A, et al: Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113:401-406
86. Higuchi T, Seki N, Kamizono S, et al: Polymorphisms of the 5′flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens 1998; 51: 605-612
87. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Nat Acad Sci U S A 1997; 94:3195-3199
88. Wilson AG, Di Giovnine FS, Blakemoor AIF, et al: Single base polymorphism in the human tumour necrosis alpha (TNFα) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1:353
89. McArthur JA, Zhang Q, Quasney MW: Association between the A/A genotype at the lymphotoxin-alpha+250 site and increased mortality in children with positive blood cultures. Pediatr Crit Care Med 2002; 3:341-344
90. Kroeger KM, Carville KS, Abraham LJ: The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997; 34:391-399
91. Quasney MW, Bronstein DE, Cantor RM, et al: Increased frequency of alleles associated with elevated tumor necrosis factor-α levels in children with Kawasaki disease. Pediatr Res 2001; 49:686-690
92. McGuire W, Hill AVS, Allsopp CEM, et al: Variations in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508-510
93. Quasney MW, Zhang Q, Sargent S, et al: Increased frequency of the tumor necrosis factor-α-308 A allele in adults with human immunodeficiency virus dementia. Ann Neuro, 2001; 50:157-162
94. Nadel S, Newport MJ, Booy R, et al: Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174:878-880
95. Mira JP, Cariou A, Grail F, et al: Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282:561-568
96. Majetschak M, Obertacke U, Schade FU, et al: Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma. Clin Diagn Lab Immunol 2002; 9:1205-1211
97. Waterer G, Quasney MW, Cantor RM, et al: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163:1599-1604
98. Stuber F, Udalova IA, Book M, et al: -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46:42-50
99. Majetschak M, Flohe S, Obertacke U, et al: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999; 230:207-2214
100. Tang GJ, Huang SL, Yien HW, et al: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Car Med 2000; 28:2733-2736
101. Schroder J, Kahlke V, Book M, et al: Gender differences in sepsis: Genetically determined? Shock 2000; 14:307-313
102. Weitkamp JH, Stuber F, Bartmann P: Pilot study assessing TNF gene polymorphism as a prognostic marker for disease progression in neonates with sepsis. Infection 2000; 28: 92-96
103. Dinarello CA, SM Wolff: The role of interleukin-1 in disease. N Engl J Med 1993; 328:106-113
104. Dinarello CA: Proinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112:321S-329S
105. Arend WP, Malyak M, Gutheridge CJ, et al: Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998; 16:27-55
106. van Deuren M, van der Ven-Jongekrijg J, Vannier E, et al: The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997; 90:1101-1108
107. Bailly S, di Giovine FS, Blakemore AL, et al: Genetic polymorphism of human interleukin-1 alpha. Eur J Immunol 1993; 23: 1240-1245
108. Dominici R, Cattaneo M, Malferrari G, et al: Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 2002; 54:82-86
109. Shirodaria S, Smith J, McKay IJ, et al: Polymorphisms in the IL-1A gene are correlated with levels of interleukin-1alpha protein in gingival crevicular fluid of teeth with severe periodontal disease. J Dent Res 2000; 79: 1864-1869
110. Bensen JT, Langefeld CD, Li L, et al: Association of an IL-1A 3′UTR polymorphism with end-stage renal disease and IL-1 alpha expression. Kidney Int 2003; 63:1211-1219
111. Pociot F, Molvig J, Wogensen L, et al: A TaqI polymorphism in the human interleukin-1 beta (IL-1beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22:396-402
112. di Giovine FS, Takhsh E, Blakemore AI, et al: Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta) Hum Mol Genet 1992; 1:450
113. Tarlow JK, Blakemore AI, Lennard A, et al: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91:403-404
114. Cox A, Camp NJ, Nicklin MJ, et al: AN analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a NOMVE grouping method for multiallelic markers. Am J Hum Genet 1998; 62:1180-1188
115. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
116. Hurme M, Anttila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28:2598-2602
117. Danis VA, Millington M, Hyland VJ, et al: Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-310
118. Ma P, Chen D, Pan J, et al: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30:1046-1050
119. Arnalich F, Lopez-Madeuruelo D, Codoceo R, et al: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-336
120. Carrol ED, Mobbs KJ, Thomson APJ, et al: Variable number tandem repeat polymorphism of the interleukin-1 receptor antagonist gene in meningococcal disease. Clin Inf Dis 2002; 35:495-497
121. Read RC, Cannings C, Naylor SC, et al: Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138: 534-541
122. Hack CE, de Groot ER, Felt-Bersma RJ, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-1710
123. Schluter B, Konig B, Bergmann U, et al: Interleukin 6-a potential mediator of lethal sepsis after major thermal trauma: Evidence for increased IL-6 production by peripheral blood mononuclear cells. J Trauma 1991; 31:1663-1670
124. Schluter B, Raufhake C, Erren M, et al: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-37
125. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275:18138-18144
126. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene in IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376
127. Kilpinen S, Hulkkonen J, Wang XY, et al: The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw. 2001; 12:62-68
128. Harding D, Dhamrait S, Millar A, et al: Is Interleukin-1-174 genotype associated with the development of septicemia in preterm infants? Pediatrics 2003; 112:800-803
129. van der Poll T, Marchant A, van Deventer SJ: The role of interleukin-10 in the pathogenesis of bacterial infection. Clin Microbiol Infect 1997; 3:605-607
130. de Waal Malefyt R, Abrams J, Bennett B, et al: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220
131. Moore KW, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765
132. Howard M, Muchamuel T, Andrade S, et al: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208
133. Gerard C, Bruyns C, Marchant A, et al: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-550
134. Steinhauser ML, Hogaboam CM, Kunkel SL, et al: IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999; 162: 392-399
135. van der Poll T, Marchant A, Keogh CV, et al: Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174:994-1000
136. Eskdale J, Kube D, Tesch H, et al: Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997; 26:120-128
137. Turner DM, Williams DM, Sankaran D, et al: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8
138. Lazarus M, Hajeer AH, Turner D, et al: Genetic variation in the interleukin10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24:2314-2317
139. Kube D, Platzer C, von Knethen A, et al: Isolation of the human interleukin 10 promoter: Characterization of the promoter activity in Burkitts lymphoma cell lines. Cytokine 1995; 7:1-7
140. Schaaf BM, Boehmke F, Esnaashari J, et al: Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168:476-480
141. Crawley E, Kay R, Sillibourne J, et al: Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arth Rheum 1999; 42: 1101-1108
142. Lowe PR, Galley HF, Abdel-Fattah A, et al: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31:34-38
143. Glynn P, Coakley R, Kilgallen I, et al: Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999; 54:512-555
144. Gallagher PM, Lowe G, Fitzgerald T, et al: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58:154-156
145. Reid CL, Perry C, Pravica V, et al: Genetic variation in proinflammatoyy and antiinflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002; 30:2216-2221
146. Deitch EA, Beck SC, Cruz NC, et al: Induction of heat shock gene expression in colonic epithelial cells after incubation with Escherichia coli or endotoxin. Crit Care Med 1995; 23:1371-1376
147. Hightower LE: Heat shock, stress proteins, chaperones and proteotoxicity. Cell 1991; 66:191-197
148. Hendrick JP, Hartl FU: Molecular chaperone functions of heat shock proteins. Annu Rev Biochem 1993; 62:349-384
149. Parsell DA, Lindquist S: The function of heat shock proteins in stress tolerance: Degradation and reactivation of damaged proteins. Annu Rev Genet 1993; 27: 437-496
150. The MHC Sequencing Consortium: Complete sequence and gene map of a human major histocompatibility complex. Nature 1999; 401:921-923
151. Poicot F, Ronningen KS, Nerup J: Polymorphic analysis of the human MHC-linked heat shock protein 70 (HSP 70-2) and HSP 70-HOM genes in insulin dependent diabetes mellitus (IDDM). Scand J Immunol 1993; 38:491-495
152. Schroeder S, Reck M, Hoeft A, et al: Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis. Crit Care Med 1999; 27:1265-1270
153. Waterer CW, ElBahlawan, Quasney MW, et al: Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 2003; 31: 1367-1372
154. Cambien F, Alhenc-Gelas F, Herbeth B, er al. Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy study. Am J Hum Genet 1988; 43:774-780
155. Rigat B, Hubert C, Alhenc-Gelas F, et al: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346
156. Tiret L, Rigat B, Visvikis S, et al: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205
157. Costerousse O, Allegrini J, Lopez M, et al: Angiotensin I converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290:33-40
158. Spruth E, Zurbrugg HR, Warnecke C, et al: Expression of ACE mRNA in the human atrial myocardium is not dependent on left ventricular function, ACE inhibitor therapy, or the ACE I/D genotype. J Mol Med 1999; 77:804-810
159. Rosatto N, Pontremoli R, De Ferrari G, et al: Intron 16 insertion of the angiotensin converting enzyme gene and transcriptional regulation. Nephrol Dial Transplant 1999; 14:868-871
160. Suehiro T, Morita T, Inoue M, et al: Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet 2004; 115:91-96
161. Harding D, Baines PB, Brull D, et al: Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002; 165:1103-1106
162. John Baier R, Loggins J, Yanamandra K: Angiotensin converting enzyme insertion/deletion polymorphism does not alter sepsis outcome in ventilated very low birth weight infants. J Perinatal 2004; Epub
163. Marshall RP, Webb S, Bellingan GJ, et al: Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650
164. Idell S, Kueppers F, Lippman M, et al: Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest 91:52-56
165. Lukkarinen H, Laine J, Lehtonen J, et al: Angiotensin II receptor blockade inhibits pneumocyte apoptosis in experimental meconium aspiration. Pediatr Res 2004; 55: 326-333
166. Aird WC: Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29:S28-S35
167. Paramo JA, Perez JL, Serrano M, et al: Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64:3-6
168. Brandtzaeg P, Joo GB, Brusletto B, et al: Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57:271-278
169. Eriksson P, Kallin B, van't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 851-1855
170. Hermans PW, Hibberd ML, Booy R, et al: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354:556-560
171. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563
172. Menges T, Hermans PW, Little SG, et al: Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357: 1096-1097
173. Floros J, Karinch AM: Human SP-A: Then and now. Am J Physiol 1995; 268: L162-L165
174. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev 1997; 77:931-962
175. LeVine AM, Kurak KE, Bruno MD, et al: Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998; 19: 700-708
176. van Iwaarden JF, Claassen E, Jeurissen SH, et al: Alveolar
177. Chiba H, Pattanajitvilai S, Mitsuzawa J, et al, Pulmonary surfactant proteins A and D recognize lipid ligands on Mycoplasma pneumoniae and markedly augment the innate immune response to the organism. Chest 2003; 123:426S
178. Wu H, et al: Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111:1589-1602
179. Cochrane CG, Revak SD: Pulmonary surfactant protein B (SP-B): Structure-function relationships. Science 1991; 254:566-568
180. Gregory TJ, Longmore WJ, Moxley MA, et al: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981
181. Greene KE, Wright JR, Steinberg KP, et al: Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160:1843-1850
182. Lin Z, Pearson C, Chinchilli V, et al: Polymorphisms of human SP-A, SP-B, and SP-D genes: Association of SP-B Thr131Ile with ARDS. Clin Genet 2000; 58:181-191
183. Pilot-Maties TJ, Kister SE, Fox JL, et al: Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B. DNA, 1989; 8:75-86
184. White RT, Hawgood S, Damm D, et al: Sequence of pulmonary surfactant protein SP18 and evidence for cooperation between SP18 and SP28-36 in surfactant lipid adsorption. Am Rev Resp Dis, 1987; 4:379A
185. Lin Z, deMello DE, Wallot M, et al: AN SP-B gene mutation responsible for SP-B deficiency in fatal congenital alveolar proteinosis: Evidence for a mutation hotspot in exon 4. Mol Genet Metab 1998; 64:25-35
186. Jacobs KA, Phelps DS, Steinbrink R, et al: Isolation of a cDNA clone encoding a high molecular weight precursor to a 6-kDa pulmonary surfactant-associated protein. J Biol Chem 1987; 292:9808-9811
187. Wang G, Christensen ND, Wigdahl B, et al: Differences in N-linked glycosylation between human surfactant protein-B variants of the C or T allele at the single-nucleotide polymorphism at position 1580: implications for disease. Biochem J 2003; 369: 179-184
188. Roberts SJ, Petropavlovskaja, Chung KN, et al: Role of individual N-linked glycosylation sites in the function and intracellular transport of the human a folate receptor. Arch Biochem Biophys 1998; 351:227-235
189. Quasney MW, GW Waterer, MK Dahmer, et al: Association between surfactant protein B+1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. Crit Care Med 2004; 32:1115-1119
190. Lazarus R, Vercelli D, Palmer LJ, et al: Single nucleotide polymorphisms in innate immunity genes: Abundant variation and potential role in complex human disease. Immunol Rev 2002; 190:9-25